Core Points - Jiangxi Tianxin Pharmaceutical Co., Ltd. held its first employee representative meeting on September 17, 2025, where Mr. Li Quanguo was elected as the employee representative director for the third board of directors [1][2] - Mr. Li Quanguo's term will last until the end of the current board's term, and he meets all legal qualifications for the position [1][2] - The company confirmed that the number of directors who are also senior management and employee representatives does not exceed half of the total number of directors [1] Meeting Details - The first temporary shareholders' meeting was held on September 17, 2025, at the company's conference room in Le Ping City, Jiangxi Province [4] - The total number of shares eligible for voting at the meeting was 435,170,280, after accounting for shares in the company's repurchase account that do not have voting rights [5] - The meeting was conducted in accordance with the Company Law and the company's articles of association, with both on-site and online voting methods used [5][6] Resolutions Passed - The meeting approved the proposal to abolish the supervisory board and amend the company's articles of association [7] - The first proposal was a special resolution that received more than two-thirds of the valid voting rights held by attending shareholders [7] Legal Verification - The meeting was witnessed by lawyers from Beijing Zhonglun (Shanghai) Law Firm, who confirmed that the meeting's procedures and voting results were in compliance with applicable laws and the company's articles of association [8]

Meeting Overview - The first extraordinary general meeting of shareholders was held on September 17, 2025, at the company's conference room in Jiangxi Province [2] - The total share capital of the company is 437,780,000 shares, with 435,170,280 shares eligible for voting after excluding repurchased shares [2] Voting and Resolutions - No resolutions were rejected during the meeting [2] - The meeting adopted a combination of on-site and online voting methods, presided over by Chairman Xu Jiangnan, in compliance with relevant laws and regulations [3] - Two key resolutions were passed: 1. The proposal to abolish the supervisory board and amend the Articles of Association [5] 2. The proposal to revise, formulate, and abolish certain corporate governance systems [5] - The first resolution required a two-thirds majority of the voting shares present to pass, which was achieved [6] Legal Verification - The meeting was witnessed by lawyers from Beijing Zhonglun (Shanghai) Law Firm, confirming that the procedures and voting were in accordance with applicable laws and the company's Articles of Association [7] Employee Representative Director Election - On September 17, 2025, the company held its first employee representative meeting, electing Li Quanguo as the employee representative director for the third board of directors [9] - Li Quanguo meets the qualifications for directorship as per relevant laws and regulations, and his term will last until the end of the current board's term [10]

证券代码：603235 证券简称：天新药业 公告编号：2025-037 江西天新药业股份有限公司 关于选举第三届董事会职工代表董事的公告 2025 年 9 月 18 日 附件： 职工代表董事简历 根据《中华人民共和国公司法》《上市公司章程指引》等法律法规、规范 性文件以及《江西天新药业股份有限公司章程》的相关规定，江西天新药业股 份有限公司（以下简称"公司"）于 2025 年 9 月 17 日召开 2025 年第一次职工 代表大会，会议选举李全国先生为公司第三届董事会职工代表董事（简历详见 附件）。李全国先生与经公司股东大会选举产生的现任非职工代表董事共同组 成公司第三届董事会，李全国先生的任期自本次职工代表大会审议通过之日起 至第三届董事会任期届满之日止。 李全国先生符合有关法律法规、规范性文件关于董事任职的资格和条件。 公司董事会中兼任公司高级管理人员职务的董事以及由职工代表担任的董事， 总计人数未超过公司董事总数的二分之一。 特此公告。 江西天新药业股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 李全 ...

北京市中伦(上海)律师事务所 关于江西天新药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年九月 北京 ・ 上海 ・ 深圳 ・ 广州 ・ 武汉 ・ 成都 ・ 重庆 ・ 背岛 ・ 杭州 ・ 南京 ・ 海口 ・ 东京 ・ 香港 ・ ・倉杉矶 ・ 浴杉矶 ・ 阿拉木图 Beijing × Slienghai ・Slenghon ・Wahn ・Chooging ・Oligitou + Hungzhu ・Hairbou ፣ Hairbu ፣ T 757 ZHONG LUN 12 中倫律師事務所 特殊的旨通合伙 Limited Liability Partnership UN 10/11/16/17F; Two IFC. 8 Century Avenue, Pudong New Area, Shanghai 200120, China 电话/Tel : +86 21 6061 3666 传真/Fax : +86 21 6061 3555 北京市中伦(上海)律师事务所 关于江西天新药业股份有限公司 2025年第一次临时股东大会的 法律意见书 致:江西天新药业股份有限公司 江西天新药业股份有限公司(下 ...

证券代码：603235 证券简称：天新药业 公告编号：2025-036 江西天新药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 17 日 (二)股东大会召开的地点：江西省景德镇市乐平市工业园工业六路江西天新药业 股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 184 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 348,031,000 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 79.9758 | | 份总数的比例（%） | | 注：截至本次股东大会股权登记日 2025 年 9 月 12 日，公司总股本为 437,780,000 股，其中公司回购专户中的股份数量为 2,609,720 股，因公司回购专户中的股份 ...

中国·江西 二〇二五年九月十七日 江西天新药业股份有限公司 2025 年第一次临时股东大会会议资料 目录 | 2025 | 年第一次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 | 3 | | | 议案一：关于取消监事会并修订《公司章程》及其附件的议案 | 4 | | | 议案二：关于修订、制定和废止部分公司治理制度的议案 | 5 | 江西天新药业股份有限公司 2025 年第一次临时股东大会 会议资料 1 江西天新药业股份有限公司 2025 年第一次临时股东大会会议资料 一、公司负责本次股东大会的议程安排和会务工作，出席会议人员应当听从公司 工作人员安排，共同维护好会议秩序。 二、为保证股东大会的正常秩序，除出席会议的股东或者股东代表、董事、监事、 高级管理人员、见证律师、本次会议议程有关人员及会务工作人员以外，公司有权拒 绝其他人员进入会场。对于影响股东大会秩序和损害其他股东合法权益的行为，公司 将按规定加以制止。 三、出席股东大会的股东、股东代表应当持身份证或者公司营业执照复印件、授 权委托书和证券账户卡等证件按股东大会通知登记时 ...

Core Viewpoint - Tianxin Pharmaceutical (603235) reported a year-on-year increase in both revenue and net profit for the first half of 2025, although there was a decline in the second quarter figures compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 reached 1.122 billion yuan, up 5.23% from 1.067 billion yuan in the same period of 2024 [1] - Net profit attributable to shareholders was 356 million yuan, reflecting a 3.14% increase from 345 million yuan in the previous year [1] - The second quarter saw total revenue of 503 million yuan, a decrease of 12.0% year-on-year, and net profit of 137 million yuan, down 30.45% [1] Profitability Metrics - Gross margin improved to 47.83%, an increase of 13.72% year-on-year, while net margin slightly decreased to 31.72%, down 1.98% [1] - Total selling, administrative, and financial expenses amounted to 71.5184 million yuan, representing 6.37% of revenue, a significant increase of 3588.88% [1] Shareholder Metrics - Earnings per share (EPS) rose to 0.82 yuan, a 3.8% increase from 0.79 yuan [1] - Net asset value per share increased to 10.69 yuan, up 8.16% from 9.87 yuan [1] - Operating cash flow per share improved significantly to 0.78 yuan, a 75.16% increase from 0.45 yuan [1] Investment Returns - The company's return on invested capital (ROIC) was reported at 13.09%, indicating strong capital returns [3] - Historical data shows a median ROIC of 40.01% since the company went public, with the lowest ROIC recorded in 2023 at 9.6% [3] Business Model Insights - The company's performance is primarily driven by capital expenditures, necessitating careful evaluation of the profitability of these investments [3]

Core Viewpoint - Jiangxi Tianxin Pharmaceutical Co., Ltd. reported a steady performance in the first half of 2025, with an increase in revenue and net profit, driven by its strong position in the vitamin industry and effective management strategies [1][2]. Company Overview and Financial Highlights - The company achieved an operating income of approximately 1.12 billion RMB, representing a 5.23% increase compared to the same period last year [2]. - The total profit reached approximately 424.59 million RMB, up by 3.54% year-on-year [2]. - The net profit attributable to shareholders was approximately 356.01 million RMB, reflecting a 3.14% increase from the previous year [2]. - The net cash flow from operating activities surged by 75.16%, primarily due to increased cash receipts from sales [2]. Business Operations - The company specializes in the research, production, and sales of single vitamins, focusing on B vitamins and other vitamin products, with a strong global market presence [6][7]. - The business is segmented into three main areas: B vitamins, other vitamins, and fine chemicals, with a diverse product portfolio [6][7]. - The company has established a robust supply chain and procurement strategy to ensure stable raw material supply and cost advantages [6][8]. Industry Position - The vitamin industry is characterized by stable demand, with growth driven by increasing global population and health awareness [6][7]. - China has become a major producer and exporter of vitamins, with the company holding a significant market share in various B vitamin products [6][7]. - The industry is undergoing consolidation, with leading manufacturers adjusting their operations to meet market demands, which is expected to improve profitability [6][7]. Competitive Advantages - The company has a comprehensive management and certification system, ensuring product quality and compliance with international standards [11][12]. - It maintains a strong focus on research and development, collaborating with academic institutions to enhance product offerings and production processes [11][12]. - The company emphasizes environmental protection and sustainability in its operations, aligning with regulatory requirements and market expectations [11][12].

Company Overview - Jiangxi Tianxin Pharmaceutical Co., Ltd. reported total assets of approximately 5.75 billion RMB at the end of the reporting period, reflecting a 2.70% increase from the previous year [1] - The net assets attributable to shareholders increased by 1.41% to approximately 4.68 billion RMB [1] Financial Performance - The company's operating revenue for the reporting period was approximately 1.12 billion RMB, representing a 5.23% increase compared to the same period last year [1] - Total profit amounted to approximately 424.59 million RMB, up by 3.54% year-on-year [1] - The net profit attributable to shareholders was approximately 356.01 million RMB, a 3.14% increase from the previous year [1] - The net profit after deducting non-recurring gains and losses was approximately 336.28 million RMB, reflecting a 2.15% increase [1] - The net cash flow from operating activities was approximately 342.00 million RMB, a significant increase of 75.16% compared to the previous year [1] - The weighted average return on net assets decreased by 0.50 percentage points to 7.42% [1] - Basic and diluted earnings per share were both 0.82 RMB, an increase of 3.80% from the previous year [1] Shareholder Information - The total number of shareholders at the end of the reporting period was 14,820 [1] - The largest shareholder, Xu Jiangnan, holds 46.51% of the shares, followed by Xu Jing with 13.50% and Wang Guangtian with 12.98% [2] - Xu Jiangnan and Xu Jing are identified as the actual controllers of the company [2]

Core Viewpoint - The board of directors of Jiangxi Tianxin Pharmaceutical Co., Ltd. held its 11th meeting of the third session on August 28, 2025, where several key resolutions were passed, including the approval of the 2025 semi-annual report and the cancellation of the supervisory board [1][2][3][4][5]. Group 1: Board Meeting Details - The meeting was conducted with all 8 directors present, ensuring compliance with relevant laws and regulations [1]. - The board approved the 2025 semi-annual report with unanimous support [2]. - A special report on the use of raised funds for the first half of 2025 was also approved without opposition [2]. Group 2: Governance Changes - The board approved the proposal to cancel the supervisory board and amend the company's articles of association, which will be submitted for shareholder approval [2][3]. - The strategic committee of the board was renamed to include ESG considerations, reflecting a commitment to enhancing the company's governance framework [3]. - Additional amendments to governance systems were approved, with some requiring shareholder review [4]. Group 3: Action Plans and Future Meetings - The board reviewed and approved the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement" action plan for 2025 [4]. - A proposal to convene the first extraordinary general meeting of shareholders in 2025 was also approved [5].